









Markets
/
Stocks
/
nasdaq-evo
/

Evotec SE

EVO

4.070USD

+0.010+0.25%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

1.45BMarket Cap

LossP/E TTM



Evotec SE

4.070

+0.010+0.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Evotec SE

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evotec SE's Score

Industry at a Glance

Industry Ranking

128 / 407

Overall Ranking

249 / 4621

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Hold

Current Rating

6.000

Target Price

+44.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Evotec SE Highlights

StrengthsRisks

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Fairly Valued

The company’s latest PE is -8.53, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.41M shares, decreasing 7.06% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.34K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.56.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 7.12, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 194.02M, representing a year-over-year decrease of 1.01%, while its net profit experienced a year-over-year decrease of 51.78%.

Score

Industry at a Glance

Previous score

7.12

Change



Financials

7.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.04

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.74

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Evotec SE's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 6.98, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -8.53, which is -44.57% below the recent high of -4.73 and -425.93% above the recent low of -44.85.

Score

Industry at a Glance

Previous score

6.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 128/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 6.67, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Evotec SE is 6.00, with a high of 7.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Hold

Current Rating

6.000

Target Price

+47.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Evotec SE

EVO

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 6.99, which is higher than the Biotechnology & Medical Research industry's average of 6.57. Sideways: Currently, the stock price is trading between the resistance level at 4.29 and the support level at 3.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.52

Change

-1.53

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.005

Buy

RSI(14)

58.059

Neutral

STOCH(KDJ)(9,3,3)

54.407

Sell

ATR(14)

0.112

Low Volatility

CCI(14)

40.886

Neutral

Williams %R

42.553

Buy

TRIX(12,20)

0.401

Sell

StochRSI(14)

7.867

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.106

Sell

MA10

4.053

Buy

MA20

3.994

Buy

MA50

3.744

Buy

MA100

3.882

Buy

MA200

3.921

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 2.65%, representing a quarter-over-quarter decrease of 0.71%. The largest institutional shareholder is CI Select Canadian Equity Fund, holding a total of 2.34K shares, representing 0.00% of shares outstanding, with 36.36% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Mubadala Investment Company PJSC

4.60M

BlackRock Institutional Trust Company, N.A.

1.32M

-12.32%

Wellington Management Company, LLP

1.21M

-36.66%

DCF Advisers, LLC

1.11M

+48.29%

Parametric Portfolio Associates LLC

303.50K

WCM Investment Management

297.91K

Pitcairn

261.18K

Envestnet Asset Management, Inc.

91.66K

Morgan Stanley Smith Barney LLC

69.63K

+8.93%

AllianceBernstein L.P.

47.65K

+149.81%

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 3.74, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.77. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.